TRIUMPHARMA LLC.

TRIUMPHARMA, founded in 2002, is a full-service CRO specializing in supporting the pharmaceutical and biotech industries by introducing new solutions to the pharmaceutical markets. The company's core strengths lie in conducting clinical trials ranging from Phase I to Phase IV, including clinical data management and BE/BA studies. With a track record of over 300+ US-FDA submissions, EU/ANSAM/Bfarm/MHRA submissions (NDAs & ANDAs), and MENA/JFDA submissions, TRIUMPHARMA has extensive experience in various therapeutic areas such as Cardiovascular diseases, Gastrointestinal disorders, Respiratory/Pulmonary disorders, Metabolic disorders, Endocrinology, Nephrology/Hepatology, Rheumatoid Arthritis, Neurology/Psychiatry, Gynecology, Infectious diseases, and Oncology.

Additionally, TRIUMPHARMA has expertise in early phase studies and a dedicated facility for Phase I-IV clinical trials conducted in compliance with ICH GCP guidelines. The company also possesses its own diagnostic and screening medical lab, bioanalytical lab equipped with state-of-the-art LC/MS/MS equipment, and a well-trained team of healthcare professionals to support various aspects of clinical trials. Furthermore, the company offers clients the advantage of its extensive experience in formulating and implementing regulatory strategies and study designs.

TRIUMPHARMA has been successfully inspected by regulatory bodies such as US-FDA, EMA, French Ministry of Health-ANSM, German Ministry of Health-Bfarm, Turkish MOH, GCC, UAE MOH, and JFDA.

TRIUMPHARMA's dedication to expertise and compliance in the clinical research field positions it as a key player in the healthcare industry and presents potential investment opportunities for venture capitalists seeking to support innovation and advancement in pharmaceutical solutions.